R-Ivac Salvage Therapy in Relapsed and Refractory DLBCL

Hematological Oncology - United Kingdom
doi 10.1002/hon.110_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Very Early FDG Pet/Ct Scan May Predict Outcomes in Relapsed or Refractory DLBCL Patients Treated With Salvage Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Poor Outcomes of Patients With Relapsed/Refractory DLBCL Requiring More Than One Salvage Therapy Followed by Autologous HCT

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pet-Adapted Nivolumab +/- Ice as Initial Salvage Therapy in Relapsed/Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Toxicity-Reduced, Myeloablative Allograft Followed by Lenalidomide Maintenance as Salvage Therapy for Refractory/Relapsed Myeloma Patients

Bone Marrow Transplantation
TransplantationHematology
2012English

Bet Inhibitor Rg6146, Venetoclax, and Rituximab Is a Highly Active Regimen in Relapsed/Refractory (R/R) Dlbcl: Initial Report of Phase 1b Safety, Biomarker, and Response Data

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Hematology International
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy